Business Context and Reporting Period
This Form 8-K Current Report was filed by Clearpoint Neuro, Inc. on November 2, 2021. The filing reports the immediate appointment of a new director to the Company's Board of Directors, increasing the Board size from seven to eight members.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Dr. Linda M. Liau, MD, PhD, MBA, was appointed as a new director effective November 2, 2021.
- Compensation Structure: Dr. Liau will receive a $40,000 annual retainer and an initial equity grant valued at $120,000 (comprising stock options and restricted stock awards).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that Dr. Liau is a Professor of Neurosurgery at UCLA and an expert in brain tumor immunology and dendritic cell-based vaccines. The Company has entered into a standard indemnification agreement with Dr. Liau, covering expenses related to her service as a director. No unusual items or specific risks were disclosed in this report.
Investor Verification Checklist
- Verify the vesting schedule for Dr. Liau's equity grant (vests on the first anniversary of the grant).
- Confirm the terms of the Non-Employee Director Compensation Plan referenced for future annual equity grants.
- Review the full text of the Indemnification Agreement (previously filed as Exhibit 10.2 on June 28, 2021) for specific liability protections.
- Check for any potential conflicts of interest given Dr. Liau's academic and research affiliations with UCLA.